Free Newsletter
Sanofi breaks ground on $477M vax plant
Sanofi-Aventis is still testing its new Dengue fever jab, but it's already broken ground on a massive new manufacturing plant in France that will churn out a huge supply of the vaccine.
Sanofi is investing $477 million--its most expensive single industrial project--in the new facility north of Lyon. And if it stays on schedule, the plant will be ready to start making the new vaccine in 2013. Sanofi CEO Chris Viehbacher (photo) says that the new vaccine, once approved, has clear potential for earning more than a billion euros a year.
"It's hard to give a precise estimate, but I wouldn't be investing 350 million euros if there wasn't a strong chance that this is the biggest vaccine ever," Viehbacher said. There are 50 million new Dengue fever infections every year.
- read the story from BusinessWeek
Related Articles:
Sanofi advances new vaccine for dengue
Sanofi launches new trial for dengue fever
Brazilian Dengue outbreak highlights vaccine need
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
